Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma

Sponsor
Olivia Newton-John Cancer Research Institute
Study ID
NCT07712770
Phase
EARLY_PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • SIR-Spheres® — DEVICE
    Single administration of SIR-Spheres® on Day 1 with optional one-time retreatment if clinically indicated

Study Details

This study is testing a new way of treating brain tumours using tiny radioactive beads called SIR-Spheres® (90Y-labelled Resin Microspheres). These microspheres are placed into the blood vessels that feed the tumour. The treatment gives off radiation inside the tumour to try to stop it from growing. This type of treatment is called Selective Internal Radiation Therapy (SIRT), Transarterial Radioembolisation (TARE), or radioembolisation. It is already an accepted treatment for patients with liver cancer. In this study, we are testing if this treatment can be done safely in the brain and how well it works.

Key Dates

First listed
Jul 17, 2026
Start date
Oct 31, 2026
Status verified
Jul 2026
Primary completion
Nov 30, 2028
Completion
Nov 30, 2028

Study Design

Enrollment
12 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Intervention
    SIR-Spheres® will be administered intra-arterially by selective catheterisation of tumour-feeding arteries. The prescribed activity will be determined on an individual basis. The administered activity of SIR-Spheres® will be selected to achieve adequate coverage of the target, taking into account tumour burden within the treated volume, while keeping dose to normal brain within acceptable limits.

Primary Outcome Measure

Safety - Treatment-related adverse events [ Time Frame: From SIR-sphere administration (Day 1) to 30 days post SIR-sphere administration. ]

Find similar trials

Nationwide
Brain cancer trialsOncology trialsNeuro-oncology trials

Related Studies